FTC

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Chronic Hepatitis BHIV-1 Infection

Phase 2

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

CompletedNCT00507507

Gilead SciencesChronic Hepatitis B

Start: 2007-09-30End: 2012-08-31Updated: 2015-07-17

Phase 3

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

CompletedNCT02616783

Gilead SciencesHIV-1 Infection

Start: 2015-12-22End: 2018-03-21Updated: 2020-03-04

Related Papers

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with <scp>HIV</scp>: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

HIV Medicine2022-05-0838 citations

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.

2021-03-0939 citations

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

2019-10-0136 citations